Sugi Predict

Sugi Predict / Compounds / SCHEMBL471041

SCHEMBL471041

SCHEMBL471041

COC(=O)c1cc([N+](=O)[O-])c(F)cc1C

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDGFRB P09619 1/20 0.62
▸ FGFR1 P11362 1/20 0.62
▸ PDGFRA P16234 1/20 0.62
▸ FLT1 P17948 1/20 0.62
▸ FGFR3 P22607 1/20 0.62
▸ KDR P35968 1/20 0.62
▸ VCAM1 P19320 1/20 0.43
▸ ITGB1 P05556 1/20 0.43
▸ ITGA5 P08648 1/20 0.43
▸ ALDH1A1 P00352 4/20 0.42
▸ PKM P14618 1/20 0.42
▸ SIRT6 Q8N6T7 1/20 0.42
▸ LMNA P02545 5/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ GALR2 O43603 1/20 0.42
▸ MITF O75030 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ HSP90AA1 P07900 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ XBP1 P17861 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14008526 0.94 PDGFRB (0.58) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL32659715 0.89 PDGFRB (0.51) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL12164843 0.88 PDGFRB (0.55) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL2247382 0.87 PDGFRB (0.50) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL1721029 0.87 PDGFRB (0.68) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL2897709 0.85 PDGFRB (0.67) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL31575920 0.84 PDGFRB (0.48) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL1560111 0.84 PDGFRB (0.47) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL1785458 0.83 MEN1 (0.48) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL1721669 0.83 PDGFRB (0.47) PDGFRBFGFR1PDGFRAFLT1FGFR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122070287-A IRAK 4-targeted degradation agent compound and application thereof 江苏先声药业有限公司 2026-05-19 — — CN disclosed
CN-119859155-A Tri-fused ring derivative inhibitor, preparation method and application thereof 江苏豪森药业集团有限公司 2025-04-22 — — CN disclosed
WO-2025077891-A1 DEGRADATION AGENT COMPOUND TARGETING IRAK4, AND USE THEREOF 江苏先声药业有限公司 2025-04-17 — — WO disclosed
EP-3885342-B1 BICYCLIC INHIBITORS OF PAD4 PADLOCK THERAPEUTICS INC (US) 2024-11-20 — — EP disclosed
US-20240368150-A1 BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER HOFFMANN-LA ROCHE INC. (US) 2024-11-07 — — US disclosed
US-20240208934-A1 ULK1/2 INHIBITORS AND THEIR USE THEREOF LIFEARC (GB) 2024-06-27 — — US disclosed
US-11976083-B2 Inhibitors of peptidylarginine deiminases GILEAD SCIENCES, INC. (US) 2024-05-07 — — US disclosed
CN-115551862-B Macrocyclic inhibitors of peptidyl arginine deiminase 吉利德科学公司 2024-04-12 — — CN disclosed
EP-4320121-A2 2,4-DIAMINOPYRIMIDINE DERIVATIVES AS ULK1/2 INHIBITORS AND THEIR USE THEREOF LifeArc (GB) 2024-02-14 — — EP disclosed
CN-117545751-A 2, 4-diaminopyrimidine derivatives as ULK1/2 inhibitors and their use 生命爱科 2024-02-09 — — CN disclosed
US-20110319385-A1 QUINOXALINE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-12-29 — — US disclosed
US-20110274655-A1 TETRAZOLONES AS INHIBITORS OF FATTY ACID SYNTHASE Infinity Pharmaceuticals (US) 2011-11-10 — — US disclosed
US-20110190278-A1 BICYCLIC HETEROCYCLIC DERIVATIVE DAINIPPON SUMITOMO PHARMA CO. 2011-08-04 — — US disclosed
US-20110190278-A1 BICYCLIC HETEROCYCLIC DERIVATIVE DAINIPPON SUMITOMO PHARMA CO. 2011-08-04 — — US disclosed
US-20110190278-A1 BICYCLIC HETEROCYCLIC DERIVATIVE DAINIPPON SUMITOMO PHARMA CO. 2011-08-04 — — US disclosed
CN-101952280-A Bicyclic heterocyclic derivative DAINIPPON SUMITOMO PHARMA CO 2011-01-19 — — CN disclosed
EP-2243779-A1 BICYCLIC HETEROCYCLIC DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2010-10-27 — — EP disclosed
EP-2243779-A1 BICYCLIC HETEROCYCLIC DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2010-10-27 — — EP disclosed
WO-2010101230-A1 QUINOXALINE COMPOUNDS アステラス製薬株式会社 (JP) 2010-09-10 — — WO disclosed
US-20080287479-A1 INHIBITORS OF SERINE PALMITOYLTRANSFERASE PFIZER INC 2008-11-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287479-A1 INHIBITORS OF SERINE PALMITOYLTRANSFERASE SPTLC1, SPTLC2, CPT1A PDGFRB 3832/4885FGFR1 4578/4885PDGFRA 4390/4885
US-20110274655-A1 TETRAZOLONES AS INHIBITORS OF FATTY ACID SYNTHASE FASN, ACSL1, HSD17B12 PDGFRB 1212/4885FGFR1 89/4885PDGFRA 1140/4885
US-11976083-B2 Inhibitors of peptidylarginine deiminases PADI4, PADI2, PADI1 PDGFRB 2177/4885FGFR1 3868/4885PDGFRA 2983/4885
US-20110190278-A1 BICYCLIC HETEROCYCLIC DERIVATIVE REN, AGTR1, AGTR2 PDGFRB 616/4885FGFR1 194/4885PDGFRA 962/4885
US-20240368150-A1 BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER BICRA, BRD4, CNR1 PDGFRB 1083/4885FGFR1 389/4885PDGFRA 658/4885
US-20240208934-A1 ULK1/2 INHIBITORS AND THEIR USE THEREOF ULK1, ULK2, ULK3 PDGFRB 2515/4885FGFR1 2615/4885PDGFRA 2873/4885
US-20110319385-A1 QUINOXALINE COMPOUND PDE9A, PDE5A, PDE3A PDGFRB 4303/4885FGFR1 4533/4885PDGFRA 4075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.